CURRENT CONCEPTS IN THE MANAGEMENT OF TETANUS

  • Y. Tkachenko Medical Institute of Sumy State University, Sumy, Ukraine
  • Y. Shkatula Medical Institute of Sumy State University, Sumy, Ukraine
  • Y. Badion Medical Institute of Sumy State University, Sumy, Ukraine
  • S. Lekishvili Medical Institute of Sumy State University, Sumy, Ukraine
  • Y. Khizhnya Medical Institute of Sumy State University, Sumy, Ukraine
Keywords: tetanus, management, benzodiazepines, magnesium sulfate, tetanus immunoglobin, tracheostomy

Abstract

The study focuses on the problem of severe tetanus cases, which continue to be reported worldwide. The population of countries with low vaccination rates, including Ukraine, is particularly at risk. Despite the increase in the level of DPT vaccination in our country among adults and children, it remains insufficient, which leads to the registration of new cases of tetanus.

 The aim of the study was to analyze the main directions in the treatment of tetanus. The authors searched for information in electronic databases such as MEDLINE/Pub Med and Google Scholar for the last 20 years. The search was performed on such terms as tetanus, treatment, benzodiazepines, tetanus immunoglobulin (medical topics). The main components of modern treatment are analyzed in the paper, which include removal of the pathogen by careful surgical treatment of wounds, rational antibiotic therapy. Drugs of choice for the eradication of vegetative forms of the pathogen are benzylpenicillin and metronidazole, but can also be used antibacterial drugs of other groups (macrolides, tetracyclines, cephalosporins). Specific immunotherapy with tetanus immunoglobulin can neutralize the toxin that freely circulates in the blood. Those who do not have vaccination data are also indicated for the introduction of tetanus toxoid. Intrathecal administration of anti-tetanus immunoglobulin remains a debatable issue. In the treatment of convulsions, drugs of the benzodiazepine group are preferred. Infusions of high doses of magnesium, dexmetomedin, baclofen, propofol or their combination can also be used. In the case of severe muscular rigidity, muscle relaxants of nondepolarizing action are used. If the spasms are prolonged, botulinum toxin A may be recommended as an injection into peripheral muscles. B-blockers (esmolol), dexmetomedin, clonidine are used to overcome autonomic dysfunction of the nervous system. Supportive therapy is important. It is aimed at providing the patient with complete nutrition. Adequate ventilation with early tracheostomy helps to avoid complications of prolonged intubation.

 The above methods can significantly reduce mortality from tetanus from 100% (in the absence of treatment) to 10%–20%.

Author Biographies

Y. Tkachenko, Medical Institute of Sumy State University, Sumy, Ukraine

Ph.D., Assistant Professor at the Department of Emergency Medicine and Disaster Medicine, Medical Institute of Sumy State University

Y. Shkatula, Medical Institute of Sumy State University, Sumy, Ukraine

Holder of Habilitation degree in Medicine, Professor, Head of the Department of Emergency Medicine and Disaster Medicine, Medical Institute of Sumy State University

Y. Badion, Medical Institute of Sumy State University, Sumy, Ukraine

Ph.D., Assistant Professor at the Department of Emergency Medicine and Disaster Medicine, Medical Institute of Sumy State University

S. Lekishvili, Medical Institute of Sumy State University, Sumy, Ukraine

Ph.D., Assistant Professor at the Department of Oncology, Medical Institute of Sumy State University

Y. Khizhnya, Medical Institute of Sumy State University, Sumy, Ukraine

Ph.D., Associate Professor at the Department of Emergency Medicine and Disaster Medicine, Medical Institute of Sumy State University

References

1. European Centre for Disease Prevention and Control. Tetanus. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019. Retrieved from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2017
2. WHO Immunological Basis for Immunization SeriesModule 3: Tetanus Update 2018. Retrieved from: https://www.who.int/immunization/documents/ISBN9789241513616/en/
3. WHO. Immunization, Vaccines and Biologicals. Tetanus. Retrieved from: https://www.who.int/immunization/diseases/tetanus/en/
4. Itzhak Brook. Current concepts in the management of Clostridium tetani infection. Expert Review of Anti-infective Therapy. 2008;6:3, 327-336, doi:10.1586/14787210.6.3.327
5. Current recommendations for treatment of tetanus during humanitarian emergencies, WHOTechnical Note, 2010. Retrieved from: https://www.who.int/diseasecontrol_emergencies/publications/who_hse_gar_dce_.2/en/.
6. Communicable Disease Management Protocols, 2017. Retrieved from: http://www.gov.mb.ca/health/publichealth/cdc/protocol/
7. Ganesh Kumar AV, Kothari VM, Krishnan A, Karnad DR. Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol. 2004;98:59–63. doi: 10.1179/000349804225003037
8. Tetanus vaccines: WHO position paper – February 2017. Retrieved from: https://www.who.int/immunization/policy/position_papers/tetanus/en/
9. Farrer JJ, Yen LM, Cook T. et al. Tetanus. J Neurol Neurosurg Psychiatry. 2000;69(3):292-301. doi: 10.1136/jnnp.69.3.292
10. Thwaites CL. Tetanus. Practical Neurology. 2002;2(3):130–7.
11. Lee DC, Lederman HM. Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis. 1992;166:642–645. doi:10.1093/infdis/166.3.642
12. Loan, Huynh & Yen, Lam & Thwaites. A Pilot Study to Assess Safety and Feasibility of Intrathecal Immunoglobulin for the Treatment of Adults with Tetanus. Am J Trop Med Hyg. 2018; 99(2): 323–326. doi: 10.4269/ajtmh.18-0153
13. Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus an evidence-based review. Crit Care. 2014;18(2): 217. doi: 10.1186/cc13797
14. Geeta MG, Krishnakumar P, Mathews L. Intrathecal tetanus immunoglobulins in the management of tetanus. Indian J Pediatr. 2007, 74, 43–45 doi: 10.1007/s12098-007-0025-y
15. Miranda-Filho Dde B, Ximenes RA, Barone AA, Vaz VL, Vieira AG, Albuquerque VM. Randomised controlled trial of tetanus treatment with anti-tetanus immunoglobulin by the intrathecal or intramuscular route. BMJ. 2004;328:615. doi: 10.1136/bmj.38027.560347.7C.
16. European Centre for Disease Prevention and Control. Retrieved from: https://www. ecdc.europa. eu/en/tetanus/facts
17. Govindaraj GM, Riyaz A. Current practicein the management of tetanus. Crit Care. 2014;18:145. doi: 10.1186/cc13894
18. Hassel B. Tetanus: Pathophysiology, Treatment, and the Possibility of Using Botulinum Toxin against Tetanus-Induced Rigidity and Spasms. Toxins (Basel). 2013;5(1):73–83. doi: 10.3390/toxins5010073
19. James S. Salonia, Mohammed Ahmed, John Cardasis. Tetanus: An Innovative Treatment Strategy for Refractory Spasticity. American Journal of Respiratory and Critical Care Medicine. 2017;195:A2017. Retrieved from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2017
20. Girgin NK, Iscimen R, Gurbet A, Kahveci F, Kutlay O. Dexmedetomidine sedation for the treatment of tetanus in the intensive care unit. Br J Anaesth. 2007;99:599-600. doi: 10.1093/bja/aem251
21. Ozer-Cinar S, Surhan, Isil CT, Paksoy I. Dexmedetomidine in the management of severe tetanus. Indian J Anaesth. 2014;58(1):96-7. doi: 10.4103/0019-5049.126847
22. Miya K, Shimojo N, Koyama Y, Enomoto Y, Hagiya K, Yamasaki Y, Nishino T, Kawano S, Mizutani T. Efficacy of concomitant use of dexmedetomidine and propofol in tetanus. The American Journal of Emergency Medicine. 2015, 33(12):1848.e3-4. doi: 10.1016/j.ajem.2015.04.069
23. Enriquez CA, Abejero JE, Ramiro P, Dioquino-Maligas CP. Rocuronium for control of refractory muscle spasms in a tetanus patient with substance abuse disorder: A case report. JNS. 2017;Vol:381:69. doi: htpps://doi.org/10.1016/j.jns.2017.08.249
24. Matak I. Evidence for central antispastic effect of botulinum toxin type A. Br J Pharmacol. 2020;177(1):65-76. doi:10.1111/bph.14846
25. Restivo, DA, Marchese–Ragona R. Botulinum toxin treatment for oropharyngeal dysphagia due to tetanus. J Neurol. 2006;253, 388–389. doi: https://doi.org/10.1007/s00415-005-0975-9
26. Botulinum toxin for muscle spasm after tetanus Tarek A-Z K Gaber, Sailaja Mannemela. J R Soc Med. 2005; Feb; 98(2): 63. doi: 10.1258/jrsm.98.2.63
27. Hogue CW Jr, Talke P, Stein PK, Richardson C, Domitrovich PP, Sessler DI. Autonomic nervous system response during sedative infusions of dexmedetomidine. Anesthesiology. 2002;97(3):592-598. doi: http://dx.doi.org/10.1097/00000542-200209000-00012
28. Goddeau RP Jr, Silverman SB, Sims JR. Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia. Neurocrit Care. 2007;7(3):217-220. doi: http://dx.doi.org/10.1007/s12028-007-0066-0
29. Maryke Spruyt GL, Van Den Heever T. The treatment of autonomic dysfunction in tetanus. S Afr J Crit Care. 2017;vol.33, n.1, pp.28-31. doi: http://dx.doi.org/10.7196/SAJCC.2017.v33i1.274
30. Elizabeth Rhinesmith and Linda Fu.Tetanus Disease, Treatment, Management.Pediatrics in Review. August 2018;39 (8) 430-432. doi: https://doi.org/10.1542/pir.2017-0238
31. Manica D, Schweiger C, Maróstica PJ, Kuhl G, Carvalho PR Association Between Length of Intubation and Subglottic Stenosis in Children.Laryngoscope. 2013;123: 1049-1054. doi: 10.1002/lary.23771
32. Awan NU, M. Sohail Z, Sarwar MM. Bashir MA. Outcome of early Tracheostomy in the management of grade II (moderate) tetanus patient. Annals of King Edward Medical University, 2017;23(4): 519-523. doi: http://dx.doi.org/10.21649/journal.akemu/2017/23.4.519.523
Published
2020-09-29
How to Cite
Y. Tkachenko, Y. Shkatula, Y. Badion, S. Lekishvili, & Y. Khizhnya. (2020). CURRENT CONCEPTS IN THE MANAGEMENT OF TETANUS . Eastern Ukrainian Medical Journal, 8(3), 242-248. Retrieved from https://eumj.med.sumdu.edu.ua/index.php/journal/article/view/118